Literature DB >> 20650653

Association between adherence to folic acid supplements and serum folate, and plasma homocysteine among hemodialysis patients.

June Leung1, Johanna Dwyer, Patricia Hibberd, Paul Jacques, William Rand, Michael V Rocco.   

Abstract

OBJECTIVE: To examine the relationship between adherence to prescribed folic acid supplements and folic acid intake, serum folate and plasma homocysteine in hemodialysis patients. The effects of change in adherence patterns from enrollment to 1 year later on changes in these same measures were also assessed.
DESIGN: Secondary data analysis. PARTICIPANTS: Eighty-six hemodialysis patients who participated in the Hemodialysis (HEMO) Study's Homocysteine ancillary study. MAIN OUTCOME MEASURES: Folic acid supplement intake, serum folate, and plasma homocysteine.
RESULTS: Eighty-eight percent of patients at enrollment and 91% 1 year later were adherent to prescribed folic acid supplements. Nonadherers had lower intakes of folic acid at both enrollment and 1 year later and lower serum folate levels at enrollment. Percent change was significantly different between the 3 adherence change groups for folic acid intake (P = .001) and plasma homocysteine (P < .001) from enrollment to 1 year later. The nonadherent group at enrollment had the lowest intakes and serum folate levels, and the highest plasma homocysteine levels. When they became adherent 1 year later, they had the greatest change in folic acid intake (5,461%; P = .03), coupled with a 69% increase in serum folate (P = .04) and a 29% decrease in plasma homocysteine (P = .03).
CONCLUSIONS: Hemodialysis patients who were nonadherent to folic acid supplement prescriptions had low folic acid intakes, low serum folates, and high homocysteine levels. When their adherence improved, folic acid intakes rose, serum folates increased, and plasma homocysteine levels decreased, although mild hyperhomocysteinemia persisted.
Copyright © 2011 National Kidney Foundation, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20650653      PMCID: PMC2962929          DOI: 10.1053/j.jrn.2010.04.005

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  57 in total

1.  Red cell or serum folate? Results from the National Pathology Alliance benchmarking review.

Authors:  M Galloway; L Rushworth
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

Review 2.  Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease.

Authors:  S S Kang; P W Wong; M R Malinow
Journal:  Annu Rev Nutr       Date:  1992       Impact factor: 11.848

3.  Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection.

Authors:  A Araki; Y Sako
Journal:  J Chromatogr       Date:  1987-11-27

4.  Vitamin levels in chronic renal failure and need for supplementation.

Authors:  G Stein; H Sperschneider; S Koppe
Journal:  Blood Purif       Date:  1985       Impact factor: 2.614

5.  Hyperhomocysteinemia: an independent risk factor for vascular disease.

Authors:  R Clarke; L Daly; K Robinson; E Naughten; S Cahalane; B Fowler; I Graham
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

6.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Authors:  James F Toole; M René Malinow; Lloyd E Chambless; J David Spence; L Creed Pettigrew; Virginia J Howard; Elizabeth G Sides; Chin-Hua Wang; Meir Stampfer
Journal:  JAMA       Date:  2004-02-04       Impact factor: 56.272

7.  Effect of dialysis dose and membrane flux in maintenance hemodialysis.

Authors:  Garabed Eknoyan; Gerald J Beck; Alfred K Cheung; John T Daugirdas; Tom Greene; John W Kusek; Michael Allon; James Bailey; James A Delmez; Thomas A Depner; Johanna T Dwyer; Andrew S Levey; Nathan W Levin; Edgar Milford; Daniel B Ornt; Michael V Rocco; Gerald Schulman; Steve J Schwab; Brendan P Teehan; Robert Toto
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

8.  Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease.

Authors:  Elizabeth M Wrone; John M Hornberger; James L Zehnder; Linda M McCann; Norman S Coplon; Stephen P Fortmann
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

9.  Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries.

Authors:  P Galan; A de Bree; L Mennen; G Potier de Courcy; P Preziozi; S Bertrais; K Castetbon; S Hercberg
Journal:  J Nutr Health Aging       Date:  2003       Impact factor: 4.075

10.  Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.

Authors:  Guido Schnyder; Marco Roffi; Yvonne Flammer; Riccardo Pin; Otto Martin Hess
Journal:  JAMA       Date:  2002-08-28       Impact factor: 56.272

View more
  1 in total

1.  Effect of folic acid combined with pravastatin on arteriosclerosis in elderly hypertensive patients with lacunar infarction.

Authors:  Chunxia Li; Xingpeng Bu; Yaru Liu
Journal:  Medicine (Baltimore)       Date:  2021-07-16       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.